ClinicalTrials.gg
CompletedNCT00195351Updated Feb 25, 2013Results posted

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection

A Phase 4 interventional study of tigecycline and ceftriaxone sodium + metronidazole in Appendicitis, Cholecystitis and Cross Infection, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 66 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-02-25.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
467
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in Appendicitis with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Appendicitis · United States.

Enrollment
9th of 59
467 · median 98
Started
2005
with 1 other
Phase 4
10 of 78
2 open now
Registered
1st of 78
by date

Among the 78 studies in Appendicitis with a site in United States, this one is the 9th largest by enrollment of the 59 interventional ones that give a count, is one of 2 that started in 2005, is one of 10 in phase 4, and was the 1st registered.

Appendicitis

421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.

Browse Appendicitis studies →

Open to participants now

6 of the 78 studies in Appendicitis with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Appendicitis studies recruiting now, 18 (46%) set no upper age limit and 19 (49%) stop at 75 or younger; 23 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Appendicitis with a site in United States, or all of them as a file.
02

Study summary

This is a phase 3b/4 randomized, open-label, comparative, multicenter study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI (Complicated Intra-Abdominal Infection). Subjects with clinical signs and symptoms of cIAI will be included for enrollment. Subjects will be stratified at randomization for Acute Physiologic and Chronic Health Evaluation scale (APACHE II) score \< 10 and > 10. Subjects will be followed for efficacy through the test-of-cure assessment. Safety evaluations will occur through the treatment and post-treatment periods and continue through resolution or stability of the adverse event(s).

03

Conditions studied

  • Appendicitis
  • Cholecystitis
  • Cross Infection
  • Diverticulitis
  • Peritonitis

Keywords

  • Complicated intra-abdominal infection
  • Appendicitis with abscess
  • Perforated diverticulitis
  • Purulent peritonitis
  • Complicated cholecystitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of complicated intra-abdominal infection that requires surgery within 24 hours.
  • Fever over 100.4°F (38.0°C) or high white blood cell count plus other symptoms such as nausea, vomiting, abdominal pain.

Exclusion criteria

Exclusion Criteria:

  • Cancer
  • Medicines that suppress the immune system
  • Dialysis
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
467 participants (actual)

Study arms

  • Active comparator
    A

    Drug: tigecycline

  • Active comparator
    B

    Drug: ceftriaxone sodium + metronidazole

Interventions

  • every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)

  • Drugceftriaxone sodium + metronidazole

    Drug pages: Ceftriaxone · Metronidazole

    Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.

06

What researchers measure

Primary outcomes

  1. Number of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit.

    The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection.

    Time frame: 10-21 days after the last dose of test article

Secondary outcomes

  1. Number of Microbiologically Evaluable Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit.

    The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection.

    Time frame: 10-21 days after the last dose of test article

  2. Number of Patients by Microbiologic Response at Test-of-Cure (TOC) Visit.

    Microbiologic response assessed at patient level was combined microbiologic responses for all baseline isolates identified in intra-abdominal/blood cultures. Eradication=baseline isolate not recovered from primary infection site/blood; Presumed Eradication=no material available for culture but response was cure; Persistence=baseline isolate recovered from primary infection site/blood; Presumed Persistence=no material available for culture but response was failure; Superinfection=culture from primary infection site was positive for new isolate not identified at baseline \& response was failure.

    Time frame: 10-21 days after the last dose of test article

07

Results

Posted Jun 10, 2009

Participant flow

Subjects were recruited worldwide from September 2005 to February 2008.

Participant flow — Overall Study
MilestoneTigecyclineCeftriaxone Sodium + Metronidazole
Started236231
Completed215215
Not completed2116
Withdrew: Lost to follow-up99
Withdrew: Withdrawal by subject63
Withdrew: Protocol deviation32
Withdrew: Death31
Withdrew: Lack of efficacy01

Outcome measures

PrimaryNumber of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit.

The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection.

Time frame:
10-21 days after the last dose of test article
Reported as:
Number · participants
Number of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit.
participantsTigecyclineCeftriaxone Sodium + Metronidazole
Number of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit.133139
Statistical analysis
  • Tigecycline vs Ceftriaxone Sodium + Metronidazole · t-test, 2 sided · p = 0.009 · Risk difference (rd): -4.0 · 95% CI -13.1 to 5.1
SecondaryNumber of Microbiologically Evaluable Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit.

The clinical response was assigned by the investigator according to the protocol-specified guidelines. A clinical response of cure was defined as: the test article and the initial intervention (operative and/or radiologically controlled drainage procedure) resolved the intra-abdominal infection.

Time frame:
10-21 days after the last dose of test article
Reported as:
Number · participants
Number of Microbiologically Evaluable Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit.
participantsTigecyclineCeftriaxone Sodium + Metronidazole
Number of Microbiologically Evaluable Patients With a Clinical Response of Cure at Test-of-Cure (TOC) Visit.9196
Statistical analysis
  • Tigecycline vs Ceftriaxone Sodium + Metronidazole · t-test, 2 sided · p = 0.020 · Risk difference (rd): -3.4 · 95% CI -14.5 to 7.8
SecondaryNumber of Patients by Microbiologic Response at Test-of-Cure (TOC) Visit.

Microbiologic response assessed at patient level was combined microbiologic responses for all baseline isolates identified in intra-abdominal/blood cultures. Eradication=baseline isolate not recovered from primary infection site/blood; Presumed Eradication=no material available for culture but response was cure; Persistence=baseline isolate recovered from primary infection site/blood; Presumed Persistence=no material available for culture but response was failure; Superinfection=culture from primary infection site was positive for new isolate not identified at baseline \& response was failure.

Time frame:
10-21 days after the last dose of test article
Reported as:
Number · participants
Number of Patients by Microbiologic Response at Test-of-Cure (TOC) Visit.
participantsTigecyclineCeftriaxone Sodium + Metronidazole
Eradication and presumed eradication9498
Persistence and presumed persistence4439
Superinfection73
Statistical analysis
  • Tigecycline vs Ceftriaxone Sodium + Metronidazole · Method of Mehrotra and Railkar · p = 0.015 · Risk difference (rd): -2.9 · 95% CI -13.9 to 8.1

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tigecycline———
Ceftriaxone Sodium + Metronidazole———
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventTigecyclineCeftriaxone Sodium + Metronidazole
AbscessGeneral disorders18/23613/231
Respiratory failureRespiratory, thoracic and mediastinal disorders2/2365/231
InfectionGeneral disorders3/2364/231
LymphoceleGeneral disorders0/2364/231
Abdominal painGeneral disorders3/2363/231
SepsisGeneral disorders0/2363/231
IleusGastrointestinal disorders3/2363/231
Intestinal obstructionGastrointestinal disorders2/2363/231
PneumoniaRespiratory, thoracic and mediastinal disorders1/2363/231
Pulmonary embolusCardiac disorders3/2361/231
Most frequent other events
Showing 10 of 40
Most frequent other events
EventTigecyclineCeftriaxone Sodium + Metronidazole
NauseaGastrointestinal disorders91/23664/231
VomitingGastrointestinal disorders55/23641/231
DiarrheaGastrointestinal disorders42/23640/231
InsominaNervous system disorders23/23624/231
AbscessGeneral disorders23/23615/231
HeadacheGeneral disorders14/23622/231
Abdominal painGeneral disorders22/23616/231
HypokalemiaMetabolism and nutrition disorders16/23621/231
LeukocytosisBlood and lymphatic system disorders19/2364/231
FeverGeneral disorders17/23618/231

Baseline characteristics

Age Continuous
Age Continuous(years)TigecyclineCeftriaxone Sodium + MetronidazoleTotal
Mean48.17 ± 18.0548.79 ± 17.4648.48 ± 17.74
Sex: Female, Male
Sex: Female, Male(Participants)TigecyclineCeftriaxone Sodium + MetronidazoleTotal
Female9372165
Male143159302
Region of Enrollment
Region of Enrollment(participants)TigecyclineCeftriaxone Sodium + MetronidazoleTotal
United States163169332
Mexico101
Canada392564
Argentina426
Brazil232346
Chile61218
08

Study locations

66 sites
  • Mobile, Alabama 36617, United States
  • Laguna Hills, California 92653, United States
  • Los Angeles, California 90033, United States
  • Orange, California 92868, United States
  • Palm Springs, California 92262, United States
  • San Diego, California 92134, United States
  • Torrance, California 90509, United States
  • Denver, Colorado 80204, United States
  • Denver, Colorado 80262, United States
  • Hartford, Connecticut 06102, United States
  • Newark, Delaware 19718, United States
  • Washington, District of Columbia 20037, United States
  • Miami, Florida 33136, United States
  • Atlanta, Georgia 30342, United States
  • Honolulu, Hawaii 96813, United States
  • Chicago, Illinois 60612, United States
  • Indianapolis, Indiana 46202, United States
  • Indianapolis, Indiana 46280, United States
  • Boston, Massachusetts 02118, United States
  • Springfield, Massachusetts 01199, United States
  • West Roxbury, Massachusetts 02132, United States
  • Detroit, Michigan 48201, United States
  • Grand Rapids, Michigan 49506, United States
  • Minneapolis, Minnesota 55422, United States
  • St. Louis, Missouri 63110, United States
  • St. Louis, Missouri 63131, United States
  • Butte, Montana 59701, United States
  • Lincoln, Nebraska 68510, United States
  • Laconia, New Hampshire 03246, United States
  • Buffalo, New York 14215, United States
  • Bismarck, North Dakota 58501, United States
  • Fargo, North Dakota 58122, United States
  • Cleveland, Ohio 44109, United States
  • Columbus, Ohio 43210, United States
  • Columbus, Ohio 43215, United States
  • Toledo, Ohio 43608, United States
  • Zanesville, Ohio 43701, United States
  • Pittsburgh, Pennsylvania 15261, United States
  • Corsiana, Texas 75151, United States
  • Fort Worth, Texas 76135, United States
  • Houston, Texas 77026, United States
  • Houston, Texas 77030, United States
  • Salt Lake City, Utah 84102, United States
  • Charlottesville, Virginia 22906, United States
  • Madison, Wisconsin 53792, United States
  • Milwaukee, Wisconsin 53226, United States
  • Buenos Aires, C1118AAT, Argentina
  • Buenos Aires, C1425DUH, Argentina
  • Buenos Aires, C1431FWO, Argentina
  • Curitiba, PR 80810-050, Brazil
  • Sao Paulo, SP 01323-010, Brazil
  • Sao Paulo, SP 04330-020, Brazil
  • Calgary, Alberta T2N 2T9, Canada
  • Victoria, British Columbia V8T 5G4, Canada
  • Ajax, Ontario L1S 2J5, Canada
  • Oshawa, Ontario L1H 1B9, Canada
  • Toronto, Ontario M1E 5E9, Canada
  • Toronto, Ontario M5T 2S8, Canada
  • Chicoutimi, Quebec G7H 5H6, Canada
  • Greenfield Park, Quebec J4V 2H1, Canada
  • Montreal, Quebec H2X 3J4, Canada
  • Rimouski, Quebec G5L 5T1, Canada
  • Trois-Rivieres, Quebec G8Z 3R9, Canada
  • Santiago, Chile
  • Vina del Mar, Chile
  • Mexico D.F. CP, 03100, Mexico
09

References and documents

Publications

  • Towfigh S, Pasternak J, Poirier A, Leister H, Babinchak T. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin Microbiol Infect. 2010 Aug;16(8):1274-81. doi: 10.1111/j.1469-0691.2010.03122.x. PubMed 20670293 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Sep 2005
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Jun 10, 2009
Last update
Feb 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00195351
Responsible party
Sponsor
First posted
Sep 19, 2005
Start date
Sep 2005
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Jun 10, 2009
Last update
Feb 25, 2013

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tigecycline · Ceftriaxone · Metronidazole

Start the discussion